Okamoto, Masaki
Fujimoto, Kiminori
Johkoh, Takeshi
Kawaguchi, Atsushi
Mukae, Hiroshi
Sakamoto, Noriho
Ogura, Takashi
Ikeda, Satoshi
Kondoh, Yasuhiro
Yamano, Yasuhiko
Komiya, Kosaku
Umeki, Kenji
Nishikiori, Hirotaka
Tanino, Yoshinori
Tsuda, Toru
Arai, Naoki
Komatsu, Masamichi
Sakamoto, Susumu
Yatera, Kazuhiro
Inoue, Yoshikazu
Miyazaki, Yasunari
Hashimoto, Seishu
Shimizu, Yasuo
Hozumi, Hironao
Ohnishi, Hiroshi
Handa, Tomohiro
Hattori, Noboru
Kishaba, Tomoo
Kato, Motoyasu
Inomata, Minoru
Ishii, Hiroshi
Hamada, Naoki
Konno, Satoshi
Zaizen, Yoshiaki
Azuma, Arata
Suda, Takafumi
Izuhara, Kenji
Hoshino, Tomoaki
Funding for this research was provided by:
Grant-in-Aid for Scientific Research (19K08637)
Kakihara Science Technology Foundation
Article History
Received: 27 April 2023
Accepted: 5 December 2023
First Online: 27 December 2023
Competing interests
: Masaki Okamoto, Hiroshi Mukae, Yasunari Miyazaki, Tomohiro Handa, Naoki Hamada, and Tomoaki Hoshino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, co., ltd. Kiminori Fujimoto received more than 1,000,000 JPY as research funding from Micron KK. Satoshi Ikeda received more than 1,000,000 JPY as research funding from Chugai pharmaceutical co., ltd. and AstraZeneca pharmaceuticals co., ltd. Kazuhiro Yatera received more than 1,000,000 JPY as research funding from FUJIFILM, co., ltd., Taiho pharmaceuticals co., ltd., GlaxoSmithKline K.K., Insmed Inc., Bayer pharmaceuticals co., ltd. Hirotaka Nishikiori received more than 1,000,000 JPY as research funding from Nippon Nippon Boehringer-Ingelheim, co., ltd. and M3, Inc., Tokyo. Yoshinori Tanino received more than 1,000,000 JPY as research funding from Nippon Boehringer-Ingelheim, co., ltd. and StemRIM Inc. Hironao Hozumi received more than 1,000,000 JPY as research funding from TERUMO LIFE SCIENCE FOUNDATION. Tomohiro Handa received more than 1,000,000 JPY as research funding from FUJIFILM, co., ltd. Hiroshi Ishii received more than 1,000,000 JPY as research funding from Shionogi pharmaceuticals co., ltd. Kenji Izuhara received more than 1,000,000 JPY as research funding from Shino test co., ltd., AstraZeneca pharmaceuticals co., ltd., and Torii Pharmaceutical co., ltd. Masaki Okamoto, Hiroshi Mukae, Noriho Sakamoto, Takashi Ogura, Yoshikazu Inoue, Yasunari Miyazaki, Motoyasu Kato, Hiroshi Ishii, Satoshi Konno, Arata Azuma and Takafumi Suda received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd. Takeshi Johkoh received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd., Kyorin Pharmaceutical co., ltd., and AstraZeneca pharmaceuticals co., ltd. Satoshi Ikeda received more than 500,000 JPY as honoraria from Ono Pharmaceutical co., ltd., Chugai pharmaceutical co., ltd., Pfizer Japan inc., AstraZeneca pharmaceuticals co., ltd., Bristol-Myers Squibb Company. Yasuhiro Kondoh and Yasuhiko Yamano received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd. and Bristol-Myers Squibb, co., ltd. Kosaku Komiya received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd. and Kyorin Pharmaceutical, co., ltd. Kazuhiro Yatera received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd., AstraZeneca pharmaceuticals co., ltd., GlaxoSmithKline K.K., Novartis Pharma, co., ltd., Kyorin Pharmaceutical, co., ltd. Toru Tsuda received more than 500,000 JPY as honoraria from AstraZeneca pharmaceuticals co., ltd. Hiroshi Ohnishi received more than 500,000 JPY as honoraria from Novartis Pharma, co., ltd. Noboru Hattori received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd., and AstraZeneca pharmaceuticals co., ltd. Takafumi Suda received more than 500,000 JPY as honoraria from Nippon Boehringer-Ingelheim, co., ltd. and AstraZeneca pharmaceuticals co., ltd. Takashi Ogura and Toru Tsuda received more than 500,000 JPY as manuscript fees from Nippon Boehringer-Ingelheim, co., ltd. Noriho Sakamoto, Yasunari Miyazaki, and Satoshi Konno received more than 1,000,000 JPY as donations from Nippon Boehringer-Ingelheim m, co., ltd. Kazuhiro Yatera received more than 1,000,000 JPY as donations from TEIJIN PHARMA co., ltd. and Taiho pharmaceuticals co., ltd. Kenji Izuhara received more than 1,000,000 JPY as donations from Shino test co., ltd. Tomohiro Handa belongs to an endowed department sponsored by TEIJIN PHARMA., co., ltd. Satoshi Konno belongs to an endowed department sponsored by Nippon Boehringer-Ingelheim m, co., ltd. Yoshikazu Inoue is a clinical trial advisor of Boehringer Ingelheim, Inc, Taiho Pharma, Kyorin Pharmaceutical co.ltd., Roche/Promedior co.ltd., Galapagos, CSL Behring, Vicore Pharma AB, Savara Inc. The enzyme-linked immunosorbent assay of periostin in the present study was performed free of charge by Shino-Test Co., Ltd. Other co-authors have no potential conflict of interest.